A retrospective real-world study strengthens evidence that early, sustained treatment with the antiamyloid lecanemab can slow ...
A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback